Dr. Sablinski is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
25
Short Hills, NJ 07078Phone+1 973-921-9115- Is this information wrong?
Summary
- I am a board certified general surgeon, who left practice some 15 years ago to became a drug developer. I have over thirty years of experience in healthcare ranging from basic research through clinical practice to drug and biologics development, in a broad international setting of Europe, Japan, and US.
I believe that the current model of clinical development is fundamentally broken, and I became passionate about changing it by:
- converging modern information technology with drug development "know-how" to increase the speed and quality of advancement of pharmaceuticals and biologics pipelines
- exploiting an unlimited potential of "knowledge networking" to revolutionize drug development and therapeutic decisions
Currently I am a managing drug development at Celtic Therapeutics, and I recently co-founded Transparency Life Sciences, the first drug development company based on open innovation crowd sourcing and cyber medicine.
www.transparencyls.com
Education & Training
- Brigham and Women's HospitalPost-Doctoral Fellowship, transplant immunology, 1988 - 1992
- Medical University of WarsawClass of 1981
Certifications & Licensure
- MA State Medical License 1996 - Present
Clinical Trials
- Efficacy and Safety Study of KIACTA in Preventing Renal Function Decline in AA Amyloidosis Start of enrollment: 2010 Nov 01
- Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca Start of enrollment: 2016 Feb 01
Publications & Presentations
PubMed
- 3 citationsOpening up clinical study design to the long tail.Tomasz Sablinski> ;Science Translational Medicine. 2014 Oct 1
- 73 citationsAcute Humoral Xenograft Rejection: Destruction of the Microvascular Capillary Endothelium in Pig-to-Nonhuman Primate Renal GraftsAkira Shimizu, Shane Meehan, Tomasz Kozlowski, T. Sablinski, Francesco L. Ierino, David K. C. Cooper, David H. Sachs, Robert B. Colvin> ;Laboratory Investigation; a Journal of Technical Methods and Pathology. 2000 Jun 1
- 10 citationsDecreased graft-versus-host disease after haplotype mismatched bone marrow allografts in miniature swine following interleukin-2 treatmentTomasz Kozlowski, T. Sablinski, M. Basker, Hiroshi Kitamura, Thomas R. Spitzer, Jay A. Fishman, Megan Sykes, David K. C. Cooper, David H. Sachs> ;Bone Marrow Transplantation. 2000 Jan 1
- Join now to see all
Professional Memberships
- The Transplantation SocietyMember
Other Languages
- Polish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: